Calltopics Ecosystem Bubbles Event Calendar

NMBP-09-2016

Biomaterials for diagnosis and treatment of demyelination disorders of the Central Nervous System -

About the connections

The graph above was generated based on the following links

Call text (as on F&T portal)

View on F&T portal
Specific Challenge:

The aim of this topic is to develop innovative approaches for biomaterials for health that are easily transferable from industry to the clinic and based on new methodologies directed to the improvement of the treatment and prognosis of demyelination disorders (one specific disorder to be chosen), where regrowth and regeneration of affected areas of the nervous system is the key to successful therapy. These disorders are often of chronic duration and associated with increasing levels of disability. In the European Union, at least 1 000 000 people are affected with these disorders and many more times than that world-wide. They are often diagnosed between the ages of 20 and 40 when families and careers are developing and can represent the most common cause of disability affecting young adults, thereby having a strong economic impact for society in terms of healthcare costs.

Scope

Proposals should focus on the development of new multifunctional biomaterials, as part of eventual Medical Devices[1] or Advanced Therapies[2], so that they can function as effective eventual therapeutic interventions. They can include biocompatible and biodegradable biomaterials as part of minimally invasive treatments and theragnostic materials. Funding for the development of new drug candidates for these conditions or for any form of clinical trial will not be considered.

The development of new integrated experimental and computational approaches aimed to describe interface processes and their determinants should be considered as key step for the design of safe and performing biomaterials. Experimental protocols should be planned taking due account of current good laboratory practice (GLP) and ISO guidelines. Manufacturing processes will need to be addressed, including up scaling, good manufacturing practice (GMP), process analytical technology (PAT), technology transfer and regulatory work in respect of relevant regulations as appropriate[3][4]. At least one type of tissue engineering construct should be delivered at the end of the research project together with a proof of concept of its therapeutic potential and preclinical validation.

In order to ensure relevance and impacts of the research efforts, the active participation of industrial partners and clinicians represents an added value to the proposals and this will be reflected in the evaluation under the criterion “Impact”. A multidisciplinary approach is preferred; taking into account both surgical, minimally invasive and pharmacological approaches, as well as prevention and rehabilitation strategies, including robotics if necessary. The expected results should improve the quality of life of the affected population and their careers. They should be measurable even for optimising research costs of the enterprises and for reducing time-to-market of new products. The project should include training and dissemination activities. As relevant, the proposed activities should address sex and gender specific aspects[5].

The implementation of this topic is intended to start at TRL 3 and target TRL 5.

This topic is particularly suitable for SMEs.

The Commission considers that proposals requesting a contribution from the EU between EUR 5 and 8 million would allow this specific challenge to be addressed appropriately. Nonetheless, this does not preclude submission and selection of proposals requesting other amounts.

Expected Impact:
  • Innovative bio/nano-materials for the treatment of patients with demyelination disorders of the Central Nervous System, improving their quality of life due to minimally invasive action and/or longer duration of implants and devices;
  • reduced direct and indirect costs linked to these diseases and their treatment;
  • enhance competitiveness of the biomaterials and biomedical industries in the EU, in particular through technology transfer effects on biotechnology companies, with particular regard to SMEs and new forms of cooperation between academia, research centres and the private sectors. Such effects should be balanced to match sustainability principles and values, and to enforce competitiveness in terms of reducing time-to-market and trial costs for European industries;
  • Dissemination of results, contributing to increase social awareness about more efficient and less costly therapies – based upon innovative approaches and broader accessibility – with improved patient compliance.

Proposals should include a business case and exploitation strategy, as outlined in the Introduction to the LEIT part of this Work Programme.

Cross-cutting Priorities:

Gender

[1] As defined by Council Directive of 20 June 1990 on the approximation of the laws of the Member States relating to Active Implantable Medical Devices (90/385/EEC) (OJ L 189, 20.7.1990, p. 17) (as amended), Council Directive 93/42/EEC of 14 June 1993 concerning Medical Devices (OJ L 169, 12.7.1993, p. 1) (as amended) and Directive 98/79/EC of the European Parliament and of the Council of 27 October 1998 on In Vitro Diagnostic Medical Devices (OJ L 331, 7.12.1998, p. 1) (as amended) and with the relevant Implementing Measures and all succeeding measures.

[2] As defined by Regulation (EC) No 1394/2007 on advanced therapy medicinal products (gene therapy, stem cell therapy and tissue engineering)

[3]As defined by Council Directive of 20 June 1990 on the approximation of the laws of the Member States relating to Active Implantable Medical Devices (90/385/EEC) (OJ L 189, 20.7.1990, p. 17) (as amended), Council Directive 93/42/EEC of 14 June 1993 concerning Medical Devices (OJ L 169, 12.7.1993, p. 1) (as amended) and Directive 98/79/EC of the European Parliament and of the Council of 27 October 1998 on In Vitro Diagnostic Medical Devices (OJ L 331, 7.12.1998, p. 1) (as amended) and with the relevant Implementing Measures and all succeeding measures.

[4]As defined by Regulation (EC) No 1394/2007 on advanced therapy medicinal products (gene therapy, stem cell therapy and tissue engineering)

[5]See definition of the 'gender dimension approach' in the introduction of this Work Programme part.

News flashes

2017-07-06

FLASH INFORMATION ON THE CALL RESULTS2017 two-stage TOPICS

Published: 14 October 2015Deadline: 4 May 2017Available budget: 235.47 M€

The Commission has now completed the evaluation of the proposals submitted to the above-mentioned call.The results of the evaluation are as follows:

Number of proposals submitted (including proposals transferred from or to other calls): 107Number of inadmissible proposals: 0Number of ineligible proposals: 0Number of above-threshold proposals: 55Total budget requested for above-threshold proposals:343.422.171 €

We recently informed the applicants about the evaluation results for their proposals.

For questions, please contact the Research Enquiry Service.

2017-05-17

DEADLINE (second stage) of 2017 two-stage topics: 04.05.17107 proposals were submitted in response to this call.The number of proposals for each topics is shown below:

NMBP-04-2017: 7NMBP-05-2017: 10NMBP-06-2017: 14NMBP-07-2017: 6NMBP-12-2017: 6NMBP-14-2017: 2NMBP-15-2017: 10NMBP-19-2017: 7NMBP-20-2017: 6NMBP-22-2017: 8NMBP-25-2017: 3NMBP-28-2017: 2NMBP-29-2017: 2NMBP-35-2017: 4BIOTEC-05-2017: 10BIOTEC-06-2017: 7BIOTEC-07-2017: 3

2017-04-27

FLASH INFORMATION ON THE CALL RESULTS H2020-NMBP-2016-2017 (2017single-stage TOPICS)

Published: 14 October 2015Deadline: 19 January 2017Available budget: CSA : 8.4 M€ + NMBP-13-2017 (X-KET): 15 M€

The Commission has now completed the evaluation of the proposals submitted to the above-mentioned call.The results of the evaluation are as follows:

CSA topicsNumber of proposals submitted (including proposals transferred from or to other calls): 16Number of inadmissible proposals: 1Number of ineligible proposals: 0Number of above-threshold proposals: 10Total budget requested for above-threshold proposals: 14,398,535.25 €

NMBP-13-2017 topicNumber of proposals submitted (including proposals transferred from or to other calls): 62Number of inadmissible proposals: 0Number of ineligible proposals: 0Number of above-threshold proposals: 7Total budget requested for above-threshold proposals: 28,946,700.00 €

We recently informed the applicants about the evaluation results for their proposals.For questions, please contact the Research Enquiry Service.

2017-02-07

Corrigendum - FLASH INFORMATION ON THE CALL RESULTS

H2020-NMBP-2016-2017 (2017 two-stage TOPICS)Please read "Deadline: 27 October 2016"

2017-01-30

FLASH INFORMATION ON THE CALL RESULTS H2020-NMBP-2016-2017 (2017 two-stage TOPICS)

Published: 14 October 2015Deadline: 27 October 2017Available budget: 235,470,000 €

The Commission has now completed the evaluation of the proposals submitted to the above-mentioned call. The following overall thresholds were applied:NMBP-04-2017 8,5/10NMBP-05-2017 8,5/10NMBP-06-2017 8,5/10NMBP-07-2017 8,5/10NMBP-22-2017 8,5/10NMBP-25-2017 8,5/10NMBP-28-2017 8,5/10NMBP-29-2017 8,5/10NMBP-35-2017 8,5/10NMBP-12-2017 8/10NMBP-14-2017 8/10NMBP-15-2017 8/10NMBP-19-2017 8/10NMBP-20-2017 8/10BIOTEC-05-2017 8/10BIOTEC-06-2017 8/10BIOTEC-07-2017 8/10

The results of the evaluation are as follows: Number of proposals submitted (including proposals transferred from or to other calls): 421Number of inadmissible proposals: -Number of ineligible proposals: 2Number of above-threshold proposals: 108Total budget requested for above-threshold proposals: 653,198,271 €We recently informed the applicants about the evaluation results for their proposals. Above-threshold proposals have been invited to submit a full proposal by 4 May 2017.Information on the selected projects will be published on CORDIS after that date. For questions, please contact the Research Enquiry Service.

2017-01-24

Deadline of 2017 single-stage topics: 19.01.2017

A total of 78 proposals were submitted in response to this call. The number of proposals for each topic is shown below:

BIOTEC-08-2017: 2NMBP-13-2017: 62NMBP-16-2017: 2NMBP-31-2017: 2NMBP-34-2017: 7NMBP-37-2017: 1NMBP-38-2017: 2

2016-11-08

Erratum: Deadline (first stage) of 2017 two-stage topics: 27.10.16

2016-11-08

Deadline (first stage) of 2017 two-stage topics: 21.10.16421 proposals were submitted in response to this call.The number of proposals for each topics is shown below:

NMBP-04-2017: 51NMBP-05-2017: 53NMBP-06-2017: 81NMBP-07-2017: 21NMBP-12-2017: 10NMBP-14-2017: 3NMBP-15-2017: 27NMBP-19-2017: 25NMBP-20-2017: 15NMBP-22-2017: 35NMBP-25-2017: 6NMBP-28-2017: 8NMBP-29-2017: 14NMBP-35-2017: 27BIOTEC-05-2017: 16BIOTEC-06-2017: 18BIOTEC-07-2017: 7

2016-09-20
The submission session is now available for: NMBP-13-2017(RIA)
2016-09-20
The submission session is now available for: NMBP-16-2017(CSA), NMBP-37-2017(CSA), NMBP-31-2017(CSA), NMBP-38-2017(CSA), BIOTEC-08-2017(CSA), NMBP-34-2017(CSA)
2016-08-03
The submission session is now available for: NMBP-06-2017(RIA), NMBP-07-2017(RIA), NMBP-05-2017(IA), NMBP-28-2017(RIA), NMBP-19-2017(RIA), NMBP-14-2017(RIA), NMBP-04-2017(RIA), NMBP-15-2017(RIA), NMBP-25-2017(IA), NMBP-12-2017(RIA), NMBP-22-2017(RIA), NMBP-20-2017(IA), NMBP-29-2017(RIA), NMBP-35-2017(RIA)
2016-08-03
The submission session is now available for: BIOTEC-06-2017(IA), BIOTEC-05-2017(RIA), BIOTEC-07-2017(RIA)
2016-07-25

Horizon 2020 Work Programme 2017 update

After the update to the Horizon 2020 Work Programme 2017 of 25 July 2016,the following updates were made:

  • Open Access Data new provisions have been added for 2017 calls with an opening date on or after 26/07/2016.
  • The introduction of the following parts have been modified: o BIOTEC topics under call H2020-NMBP-2016-17. o MODELLING topics under call H2020-NMBP-2016-17
  • The text for evaluation criteria, scoring, threshold and procedure has been clarified.
  • The text for topics NMBP-22-2017, BIOTEC-05-2017, BIOTEC-06-2017 and BIOTEC-07-2017 has been modified.
  • The following two new CSA topics have been added to the call H2020-NMBP-2017: o NMBP-37-2017 Mapping a path to future supply chains o NMBP-38-2017 Support for the enhancement of the impact of PILOT projects.
  • Other Action 5. Exploitation Strategy and Innovation Consultants (ESIC) has been cancelled. Other Action 6. Exploitation Strategy and Innovation Consultants (ESIC) has been changed to other action 5. Exploitation Support Services and the text has been revised.
  • The following new actions have been added: o 8. Study on due diligence and risk assessment of KETs projects by investors o 9. Best practise for identifying and assessing the dual-use issues in enabling technologies research – preliminary study o 10. Addressing dual-use issues in enabling technologies research
  • The indicative budget for call H2020-NMBP-2017 was increased to €253.87 million in 2017.

2016-07-12

Flash Call Info

Call identifier: H2020-NMBP-2016-2017 (2016 Two-stage topics)Call title: Call for Nanotechnologies, Advanced materials, Biotechnology and ProductionPublished: 14 October 2015Deadline: 24 May 2016 17:00:00

Budget available: 174.08 M€

  • BIOTEC-02-2016 03-2016: 32 M€
  • NMBP-01-2016 + 020-2016 + 03-2016 + 23-2016 + 26-2016: 78.08 M€
  • NMBP-09-2016 + 10-2016: 32 M€
  • NMBP-17-2016 + 18-2016: 32M€

The Commission has completed the evaluation of the proposals submitted to the above call. The results of the evaluation are as follows:

TOPICS BIOTEC-02-2016 + 03-20016Number of proposals submitted (including proposals transferred from or to other calls): 17Number of inadmissible proposals: 0Number of ineligible proposals: 0Number of above-threshold proposals: 8Total budget requested for above-threshold proposals: 48,417,925 €

NMBP-01-2016 + 020-2016 + 03-2016 + 23-2016 + 26-2016Number of proposals submitted (including proposals transferred from or to other calls): 36Number of inadmissible proposals: 0Number of ineligible proposals: 0Number of above-threshold proposals: 20Total budget requested for above-threshold proposals: 116,470,292 €

NMBP-09-2016 + 10-2016Number of proposals submitted (including proposals transferred from or to other calls):16Number of inadmissible proposals: 0Number of ineligible proposals: 0Number of above-threshold proposals: 6Total budget requested for above-threshold proposals: 34,039,531 €

NMBP-17-2016 + 18-2016Number of proposals submitted (including proposals transferred from or to other calls): 15Number of inadmissible proposals: 0Number of ineligible proposals: 0Number of above-threshold proposals: 6Total budget requested for above-threshold proposals: 32,301,327 €

We recently informed the applicants about the evaluation results for their proposals.

The number of proposals that can finally be funded depends on the available budget and the formal approval of grant agreements by the Commission.

It is expected that the first grant agreements will be signed by November 2016.

Information on the selected projects will be published on CORDIS after that date.http://cordis.europa.eu/projects/home_en.html

In case of questions, please contact the Research Enquiry Servicehttp://ec.europa.eu/research/enquiries

2016-04-19

An overview of the following evaluation results (flash call info) is now available under the tab Topic conditions and documents:

  • 2016 NMBP single stage topics
  • 2016 NMBP two-stage topics (first stage results)
2016-01-25

Deadline of 2016 single stage topics: 21.01.1638 proposals were submitted in response to this call.The number of proposals for each topics is shown below:

Type of Action: CSA

BIOTEC-04: 3NMBP-24: 1NMBP-27: 2 NMBP-30: 1NMBP-31: 2NMBP-32: 1NMBP-33: 4NMBP-36: 1

Type of Action ERANET-co-FUND

BIOTEC-01: 2NMBP-11: 1NMBP-21: 1

Type of Action RIA (Green Vehicles topic)

NMBP-08: 19

2015-12-14

Deadline (first stage) of 2016 two-stage topics: 08.12.15305 proposals were submitted in response to this call.The number of proposals for each topics is shown below:

NMBP-01-2016: 25NMBP-02-2016: 17NMBP-03-2016: 37NMBP-09-2016: 17NMBP-10-2016: 61NMBP-17-2016: 42NMBP-18-2016: 4NMBP-23-2016: 9NMBP-26-2016: 17BIOTEC-02-2016: 47BIOTEC-03-2016: 29

call topic details
Call status: Closed
Opening date: 2015-10-15 (10 years ago)
Closing date: 2015-12-08 (10 years ago)
Procedure: two-stage

Budget: 32,000,000
Expected grants: not specified
News flashes

This call topic has been appended 17 times by the EC with news.

  • 2017-07-06
    flash information on the call results201...
  • 2017-05-17
    deadline (second stage) of 2017 two-stag...
  • 2017-04-27
    flash information on the call results h2...
  • 2017-02-07
    corrigendum - flash information on the c...
  • 2017-01-30
    flash information on the call results h2...
  • 2017-01-24
    deadline of 2017 single-stage topics: 19...
  • 2016-11-08
    erratum: deadline (first stage) of 2017...
  • 2016-11-08
    deadline (first stage) of 2017 two-stage...
  • 2016-09-20
    the submission session is now available...
  • 2016-09-20
    the submission session is now available...
  • 2016-08-03
    the submission session is now available...
  • 2016-08-03
    the submission session is now available...
  • 2016-07-25
    horizon 2020 work programme 2017 updatea...
  • 2016-07-12
    flash call infocall identifier: h2020-nm...
  • 2016-04-19
    an overview of the following evaluation...
  • 2016-01-25
    deadline of 2016 single stage topics: 21...
  • 2015-12-14
    deadline (first stage) of 2016 two-stage...
Call

H2020-NMBP-2016-2017

Call topics are often grouped together in a call. Sometimes this is for a thematic reason, but often it is also for practical reasons.

There are 46 other topics in this call:

Source information

Showing the latest information. Found 1 version of this call topic in the F&T portal.

Information from

  • 2024-03-30_14-22-23

Annotations

You must be logged in to add annotations
No annotations yet

Events

This is just a very first implementation, better visualisation coming

Events are added by the ideal-ist NCP community and are hand-picked. If you would like to suggest an event, please contact idealist@ffg.at.

Call topic timeline

What phase of the topic timeline are we in? This timeline contains some suggestions on what are realistic actions you should or could take at this moment. The timeline is based on the information provided by the call topic.

  1. Work programme available

    - 10 years ago

    The call topics are published first in the Work Programme, which is available a while before the call opens. By following up the Work Programme publications, you can get a headstart.

  2. Opening date

    - 10 years ago

    The call opened for submissions.

  3. Closing date

    - 10 years ago

    Deadline for submitting a project.

  4. Time to inform applicants Estimate

    - 9 years ago

    The maximum time to inform applicants (TTI) of the outcome of the evaluation is five months from the call closure date.

  5. Sign grant agreement Estimate

    - 9 years ago

    The maximum time to sign grant agreements (TTG) is three months from the date of informing applicants.

  6. Publication date

    - 1 year ago

    The call was first imported in TopicTree.

  7. Today

Funded Projects

Loading...

Project information comes from CORDIS (for Horizon 2020 and Horizon Europe) and will be sourced from F&T Portal (for Digital Europe projects)

Bubbles

This call topic is part of:

Call document info

This section will come soon and contain the scraped information from the call document, such as the expected impact, scope, and other relevant sections. In the meantime, you can find this information in the call text section or directly on the F&T portal. View on F&T portal